14-9159-82

antibody from Invitrogen Antibodies

Targeting: DSG2 CDHF5

Immunocytochemistry (Supportive data in Antibodypedia)

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

14-9159-82

Provider

Invitrogen Antibodies

Product name

Desmoglein 2 Monoclonal Antibody (CSTEM28), eBioscience™

Antibody type

Monoclonal

Antigen

Other

Description

This monoclonal antibody CSTEM28 reacts with human desmoglein 2 (DSG2), a type 1 transmembrane protein belonging to the cadherin family. DSG2 is expressed by epithelial cells, cardiomyocytes, endothelial progenitors, and CD34+CD45dim hematopoietic stem and progenitor cells. This adhesion molecule forms cell-cell adhesion complexes called desmosomes that provide tensile strength to tissues that experience mechanical stress. Other than its role in desmosome formation, DSG2 plays a role in barrier integrity, adhesion, migration, cell apoptosis, proliferation, vasculogenic mimicry, and intracellular signaling. DSG2-expressing endothelial progenitor cells are pro-angiogenic, suggesting a role in vasculature formation. On hematopoietic stem and progenitor cells, DSG2 expression is highest on CD38-CD90+ multi-potent cells. DSG2 expression is progressively decreased as a function of differentiation, with DSG2 expression absent on mature lymphocytes. DSG2 also serves as a receptor for adenoviruses and can be shed by mucosal barriers in the intestine. This CSTEM28 antibody has been tested by flow cytometric analysis of the 2102ep cell line. This has also been tested by immunocytochemistry of fixed and permeabilized cells and can be used at less than or equal to 10 µg/mL. It is recommended the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 µm post-manufacturing filtered.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

CSTEM28

Vial size

100 µg

Concentration

0.5 mg/mL

Storage

4° C, store in dark, DO NOT FREEZE!

References

Submitted references

Comparative Analysis of Cell-Cell Contact Abundance in Ovarian Carcinoma Cells Cultured in Two- and Three-Dimensional In Vitro Models.

Kutova OM, Sencha LM, Pospelov AD, Dobrynina OE, Brilkina AA, Cherkasova EI, Balalaeva IV
Biology 2020 Dec 4;9(12)

---

Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor.

Kuryk L, Møller AW
Journal of medical virology 2020 Aug;92(8):1309-1315

---

Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model.

Kuryk L, Møller AW, Jaderberg M
Oncoimmunology 2019;8(2):e1532763

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunocytochemistry of fixed and permeabilized 2102EP cells using 10 µg/mL Anti-Human Desmoglein 2 Purified followed by F (ab')2 Anti-Mouse IgG eFluor® 660. Nuclei are stained with DAPI.

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Staining of a mixture of iPSC and the C2C12 cell line with 0.25 µg of Mouse IgG2b K Isotype Control Purified (Product # 14-4732-82) (blue histogram) or 0.25 µg of Anti-Human Desmoglein 2 Purified (purple histogram) followed by F (ab')2 Anti-Mouse IgG PE (Product # 12-4010-82). Total viable cells were used for analysis.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 3 Expression level of analyzed proteins of adherens junctions (E-cadherin), desmosomes (desmoglein-2) and gap junctions (connexin-43) in SKOV-3 and SKOV-3.ip cells cultured in monolayer and 3D in vitro models. ( A , C , E ) The distributions of SKOV-3 cells (left plot) and SKOV-3.ip cells (right plot) according to fluorescence intensity detected after staining with E-cadherin-specific, desmoglein-2-specific and connexin-43-specific antibodies (red-monolayer culture, blue-spheroids, green-collagen hydrogel); ( B , D , F ) Levels of E-cadherin, desmoglein-2 and connexin-43 in monolayer and 3D models denoted as relative fluorescence values, calculated as a ratio of mean fluorescence intensity of cells stained with specific antibodies to mean fluorescence intensity of cells stained with antibodies of isotypic control. mnlr , monolayer; sph , spheroids; clgn , collagen hydrogel. ""*"" indicates significant difference in RF level from monolayer culture (ANOVA, Holm-Sidak''s multiple comparisons test, p < 0.05).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 1 EOC receptor expression and sensitivity to oncolytic activity to ONCOS-102 treatment. A, Flow cytometry analyses of CAR, CD46, and DSG2 receptor expression on ovarian cancer cells. At least 10 4 events were analyzed for each marker and cell line. Results represent the mean +- SEM of at least two independent experiments. Cell viability at (B) 72 hours or (C) 96 hours after ONCOS-102 treatment in five different concentrations was assessed with the MTS assay. Results are expressed as the mean percent of untreated cells +- SEM. Data represents a pool of two independent experiments run in triplicate. CAR, coxsackie and adenovirus receptor; DSG2, desmoglein-2; EOC, epithelial ovarian cancer

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

10.1080/2162402X.2018.1532763-F0001 Figure 1. Expression of CAR, CD46, Desmoglein-2 and PD-L1 in human melanoma cells measured by flow cytometry (at least 10 4 cells/events were analyzed by flow cytometry in one replicate experiment). Data are expressed as percentage of cells positive for the marker.